TIBET AIM PHARM released its performance for the first half of the year, with a net profit attributable to the parent company of 37.5571 million yuan, a year-on-year decrease of 5.27%
TIBET AIM PHARM released its semi-annual report for 2025, with operating revenue of 311 million yuan, a year-on-year decrease of 11.52%; net profit attributable to the parent company was 37.5571 million yuan, a year-on-year decrease of 5.27%; net profit excluding non-recurring gains and losses was 25.0222 million yuan, a year-on-year increase of 102.33%; basic earnings per share were 0.2 yuan
According to the Zhitong Finance APP, TIBET AIM PHARM (002826.SZ) released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 311 million yuan, a year-on-year decrease of 11.52%. The net profit attributable to shareholders of the listed company was 37.5571 million yuan, a year-on-year decrease of 5.27%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 25.0222 million yuan, a year-on-year increase of 102.33%. The basic earnings per share were 0.2 yuan
